Exscientia AI Ltd.

Recursion's Oncology Drugs REC-3565 and REC-4539 Advance to Clinical Trials

5 months ago

• Recursion's REC-3565, a MALT1 inhibitor for B-cell malignancies, has been cleared for a Phase 1 clinical trial by the UK MHRA, addressing unmet needs in hematologic cancers. • The FDA has cleared Recursion's REC-4539, a reversible LSD1 inhibitor, for a Phase 1/2 trial targeting small-cell lung cancer, designed to penetrate the CNS for enhanced efficacy. • REC-3565 aims to reduce hyperbilirubinemia risks, while REC-4539 targets brain metastases common in SCLC, potentially improving outcomes for approximately 86,000 patients annually in the US+EU5. • Both drugs exemplify Recursion's precision design approach, leveraging its OS platform and AI to optimize molecules with unique properties for precision medicine.